204 related articles for article (PubMed ID: 36565895)
1. CDK inhibitors from past to present: A new wave of cancer therapy.
Mughal MJ; Bhadresha K; Kwok HF
Semin Cancer Biol; 2023 Jan; 88():106-122. PubMed ID: 36565895
[TBL] [Abstract][Full Text] [Related]
2. CDK inhibitors in cancer therapy, an overview of recent development.
Zhang M; Zhang L; Hei R; Li X; Cai H; Wu X; Zheng Q; Cai C
Am J Cancer Res; 2021; 11(5):1913-1935. PubMed ID: 34094661
[TBL] [Abstract][Full Text] [Related]
3. Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
Giannone G; Tuninetti V; Ghisoni E; Genta S; Scotto G; Mittica G; Valabrega G
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31083638
[TBL] [Abstract][Full Text] [Related]
4. Naturally Sourced CDK Inhibitors and Current Trends in Structure-Based Synthetic Anticancer Drug Design by Crystallography.
Nandi S; Dey R; Dey S; Samadder A; Saxena AK
Anticancer Agents Med Chem; 2022; 22(3):485-498. PubMed ID: 34503422
[TBL] [Abstract][Full Text] [Related]
5. An Overview of CDK Enzyme Inhibitors in Cancer Therapy.
Mounika P; Gurupadayya B; Kumar HY; Namitha B
Curr Cancer Drug Targets; 2023; 23(8):603-619. PubMed ID: 36959160
[TBL] [Abstract][Full Text] [Related]
6. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies-Current Understanding, (Pre-)Clinical Application and Promising Approaches.
Richter A; Schoenwaelder N; Sender S; Junghanss C; Maletzki C
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065376
[TBL] [Abstract][Full Text] [Related]
8. A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors.
Akin S; Babacan T; Sarici F; Altundag K
J BUON; 2014; 19(1):42-6. PubMed ID: 24659641
[TBL] [Abstract][Full Text] [Related]
9. The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.
Jhaveri K; Burris Rd HA; Yap TA; Hamilton E; Rugo HS; Goldman JW; Dann S; Liu F; Wong GY; Krupka H; Shapiro GI
Expert Rev Anticancer Ther; 2021 Oct; 21(10):1105-1124. PubMed ID: 34176404
[No Abstract] [Full Text] [Related]
10. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
11. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
12. The Role of CDKs and CDKIs in Murine Development.
Campbell GJ; Hands EL; Van de Pette M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32731332
[TBL] [Abstract][Full Text] [Related]
13. Metabolomic Applications to the Characterization of the Mode-of-Action of CDK Inhibitors.
Palomino-Schätzlein M; Pineda-Lucena A
Methods Mol Biol; 2016; 1336():211-23. PubMed ID: 26231718
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
Susanti NMP; Tjahjono DH
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase inhibitors (CDKIs) and the DNA damage response: The link between signaling pathways and cancer.
Amani J; Gorjizadeh N; Younesi S; Najafi M; Ashrafi AM; Irian S; Gorjizadeh N; Azizian K
DNA Repair (Amst); 2021 Jun; 102():103103. PubMed ID: 33812232
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological relevance of CDK inhibitors in Alzheimer's disease.
Malhotra N; Gupta R; Kumar P
Neurochem Int; 2021 Sep; 148():105115. PubMed ID: 34182065
[TBL] [Abstract][Full Text] [Related]
17. Targeting cyclin-dependent kinases in gastrointestinal cancer therapy.
Zhang J; Su G; Lin Y; Meng W; Lai JKL; Qiao L; Li X; Xie X
Discov Med; 2019 Jan; 27(146):27-36. PubMed ID: 30721649
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction.
Tong J; Tan X; Hao S; Ermine K; Lu X; Liu Z; Jha A; Yu J; Zhang L
Oncogene; 2023 Mar; 42(12):869-880. PubMed ID: 36721000
[TBL] [Abstract][Full Text] [Related]
19. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
20. From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.
Shi Z; Tian L; Qiang T; Li J; Xing Y; Ren X; Liu C; Liang C
J Med Chem; 2022 May; 65(9):6390-6418. PubMed ID: 35485642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]